BE2015C007I2 - - Google Patents

Download PDF

Info

Publication number
BE2015C007I2
BE2015C007I2 BE2015C007C BE2015C007C BE2015C007I2 BE 2015C007 I2 BE2015C007 I2 BE 2015C007I2 BE 2015C007 C BE2015C007 C BE 2015C007C BE 2015C007 C BE2015C007 C BE 2015C007C BE 2015C007 I2 BE2015C007 I2 BE 2015C007I2
Authority
BE
Belgium
Application number
BE2015C007C
Other languages
French (fr)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33551775&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2015C007(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BE2015C007I2 publication Critical patent/BE2015C007I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C07K14/503—Fibroblast growth factor [FGF] basic FGF [bFGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BE2015C007C 2003-06-12 2015-02-02 BE2015C007I2 (US07576130-20090818-C00078.png)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47788003P 2003-06-12 2003-06-12
PCT/US2004/015595 WO2005000892A2 (en) 2003-06-12 2004-06-10 Glp-1 analog fusion plroteins

Publications (1)

Publication Number Publication Date
BE2015C007I2 true BE2015C007I2 (US07576130-20090818-C00078.png) 2023-08-09

Family

ID=33551775

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2015C007C BE2015C007I2 (US07576130-20090818-C00078.png) 2003-06-12 2015-02-02

Country Status (29)

Country Link
US (2) US7452966B2 (US07576130-20090818-C00078.png)
EP (2) EP1641823B1 (US07576130-20090818-C00078.png)
JP (1) JP4629047B2 (US07576130-20090818-C00078.png)
KR (1) KR100758755B1 (US07576130-20090818-C00078.png)
CN (2) CN101974090B (US07576130-20090818-C00078.png)
AR (1) AR044776A1 (US07576130-20090818-C00078.png)
AT (1) ATE525395T1 (US07576130-20090818-C00078.png)
AU (1) AU2004251145C1 (US07576130-20090818-C00078.png)
BE (1) BE2015C007I2 (US07576130-20090818-C00078.png)
BR (1) BRPI0411132B8 (US07576130-20090818-C00078.png)
CA (1) CA2528591C (US07576130-20090818-C00078.png)
CY (2) CY1111991T1 (US07576130-20090818-C00078.png)
DK (1) DK1641823T3 (US07576130-20090818-C00078.png)
EA (1) EA008831B1 (US07576130-20090818-C00078.png)
ES (1) ES2371072T3 (US07576130-20090818-C00078.png)
FR (1) FR15C0010I2 (US07576130-20090818-C00078.png)
HK (1) HK1149566A1 (US07576130-20090818-C00078.png)
HR (1) HRP20110714T1 (US07576130-20090818-C00078.png)
HU (1) HUS1500024I1 (US07576130-20090818-C00078.png)
IL (1) IL171926A (US07576130-20090818-C00078.png)
LT (1) LTC1641823I2 (US07576130-20090818-C00078.png)
MX (1) MXPA05013565A (US07576130-20090818-C00078.png)
NZ (1) NZ543292A (US07576130-20090818-C00078.png)
PL (1) PL1641823T3 (US07576130-20090818-C00078.png)
PT (1) PT1641823E (US07576130-20090818-C00078.png)
SI (1) SI1641823T1 (US07576130-20090818-C00078.png)
TW (1) TW200507870A (US07576130-20090818-C00078.png)
UA (1) UA87458C2 (US07576130-20090818-C00078.png)
WO (1) WO2005000892A2 (US07576130-20090818-C00078.png)

Families Citing this family (166)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
KR100988949B1 (ko) * 2001-10-25 2010-10-20 제넨테크, 인크. 당단백질 조성물
EP1463751B1 (en) 2001-12-21 2013-05-22 Human Genome Sciences, Inc. Albumin fusion proteins
WO2003059934A2 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
US20070161087A1 (en) * 2003-05-29 2007-07-12 Wolfgang Glaesner Glp-1 fusion proteins
WO2005000892A2 (en) * 2003-06-12 2005-01-06 Eli Lilly And Company Glp-1 analog fusion plroteins
AU2005211725B2 (en) 2004-02-09 2010-07-15 Human Genome Sciences, Inc. Albumin fusion proteins
WO2006068910A1 (en) * 2004-12-22 2006-06-29 Eli Lilly And Company Glp-1 analog fusion protein formulations
DE602006017202D1 (de) * 2005-05-13 2010-11-11 Lilly Co Eli Pegylierte glp-1-verbindungen
WO2007012188A1 (en) * 2005-07-27 2007-02-01 Qinghua Wang GLP/1/EXENDM 4 IgG Fc FUSION CONSTRUCTS FOR TREATMENT OF DIABETES
WO2007016764A1 (en) 2005-08-06 2007-02-15 Qinghua Wang Composition and method for prevention and treatment of type i diabetes
ES2336575T3 (es) * 2005-09-22 2010-04-14 Biocompatibles Uk Limited Polipeptidos de fusion glp-1 (peptido-1 similar al glucagon) con resistencia aumentada a la peptidasa.
WO2007067828A2 (en) * 2005-10-24 2007-06-14 Centocor, Inc. Glp-2 mimetibodies, polypeptides, compositions, methods and uses
LT1965823T (lt) 2005-11-04 2016-10-10 Glaxosmithkline Llc Hipoglikeminių agentų skyrimo būdai
EP2570133B1 (en) * 2005-11-07 2016-03-23 Indiana University Research and Technology Corporation Glucagon analogs exhibiting physiological solubility and stability
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US8841255B2 (en) 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
EP2007804B1 (en) 2006-04-20 2014-06-18 Amgen, Inc Glp-1 compounds
JP5290177B2 (ja) * 2006-08-31 2013-09-18 セントカー・インコーポレーテツド Ｇｌｐ−２ミメティボディ、ポリペプチド、組成物、方法および用途
JP5395664B2 (ja) * 2006-09-06 2014-01-22 フェーズバイオ ファーマシューティカルズ，インコーポレイテッド 融合ペプチド治療用組成物
US8338376B2 (en) * 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
AU2007338298B2 (en) 2006-12-22 2013-02-07 Csl Behring Gmbh Modified coagulation factors with prolonged in vivo half-life
US20090098130A1 (en) * 2007-01-05 2009-04-16 Bradshaw Curt W Glucagon-like protein-1 receptor (glp-1r) agonist compounds
AU2011254001B2 (en) * 2007-01-05 2012-08-02 Covx Technologies Ireland Limited Glucagon-like protein-1 receptor (GLP-1R) agonist compounds
JP2008169195A (ja) * 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
ES2628063T3 (es) * 2007-01-05 2017-08-01 Indiana University Research And Technology Corporation Análogos de glucagón que muestran una mayor solubilidad en tampones de pH fisiológicos
DK2526962T3 (da) 2007-02-12 2019-10-07 Csl Behring Gmbh Therapeutic application of Kazal-type serine protease inhibitors
MX2009008241A (es) 2007-02-15 2009-10-08 Univ Indiana Res & Tech Corp Co-agonistas de receptor de glucagon/glp-1.
CN101951940A (zh) * 2007-03-15 2011-01-19 比奥根艾迪克Ma公司 自身免疫病的治疗
JP5646848B2 (ja) * 2007-06-19 2014-12-24 株式会社糖鎖工学研究所 糖鎖付加ｇｌｐ−１ペプチド
US7960336B2 (en) * 2007-08-03 2011-06-14 Pharmain Corporation Composition for long-acting peptide analogs
WO2009020802A2 (en) * 2007-08-03 2009-02-12 Eli Lilly And Company Treatment for obesity
US8563527B2 (en) * 2007-08-20 2013-10-22 Pharmain Corporation Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same
EP2031064A1 (de) * 2007-08-29 2009-03-04 Boehringer Ingelheim Pharma GmbH & Co. KG Verfahren zur Steigerung von Proteintitern
EP2214691B1 (en) * 2007-10-30 2015-09-30 Indiana University Research and Technology Corporation Compounds exhibiting glucagon antagonist and glp-1 agonist activity
ES2509883T3 (es) 2007-10-30 2014-10-20 Indiana University Research And Technology Corporation Antagonistas de glucagón
US20100317057A1 (en) * 2007-12-28 2010-12-16 Novo Nordisk A/S Semi-recombinant preparation of glp-1 analogues
WO2009099763A1 (en) * 2008-01-30 2009-08-13 Indiana University Research And Technology Corporation Ester-based peptide prodrugs
JOP20190083A1 (ar) 2008-06-04 2017-06-16 Amgen Inc بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
JP5753779B2 (ja) * 2008-06-17 2015-07-22 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ 生理学的ｐＨの緩衝液中で向上した溶解性及び安定性を示すグルカゴン類縁体
DK2300035T3 (en) * 2008-06-17 2015-11-16 Univ Indiana Res & Tech Corp Mixed GIP-based agonists for the treatment of metabolic diseases and obesity
EP2300037B1 (en) 2008-06-17 2016-03-30 Indiana University Research and Technology Corporation Glucagon/glp-1 receptor co-agonists
CA2728012C (en) 2008-06-24 2017-10-31 Csl Behring Gmbh Factor viii, von willebrand factor or complexes thereof with prolonged in vivo half-life
WO2009158704A2 (en) 2008-06-27 2009-12-30 Duke University Therapeutic agents comprising elastin-like peptides
PE20120021A1 (es) 2008-10-10 2012-02-10 Amgen Inc Mutantes fgf21
AR074811A1 (es) 2008-12-19 2011-02-16 Univ Indiana Res & Tech Corp Profarmaco de peptido de la superfamilia de glucagon basados en amida
US9238878B2 (en) 2009-02-17 2016-01-19 Redwood Bioscience, Inc. Aldehyde-tagged protein-based drug carriers and methods of use
WO2010129600A2 (en) 2009-05-05 2010-11-11 Amgen Inc. Fgf21 mutants and uses thereof
US8188040B2 (en) 2009-05-05 2012-05-29 Amgen Inc. FGF21 mutants and uses thereof
JP5887265B2 (ja) 2009-06-16 2016-03-16 インディアナ・ユニバーシティ・リサーチ・アンド・テクノロジー・コーポレーション Ｇｉｐ受容体活性グルカゴン化合物
EP2443145A1 (en) * 2009-06-17 2012-04-25 Amgen, Inc Chimeric fgf19 polypeptides and uses thereof
CN101993485B (zh) 2009-08-20 2013-04-17 重庆富进生物医药有限公司 促胰岛素分泌肽类似物同源二聚体及其用途
KR101229610B1 (ko) * 2009-10-09 2013-02-05 한남대학교 산학협력단 Ｇｌｐ-1 유사체의 융합체, 및 이를 유효성분으로 함유하는 당뇨병의 예방 또는 치료용 조성물
US8372952B2 (en) * 2009-12-02 2013-02-12 Amgen Inc. Binding proteins that bind to human FGFR1C, human β-klotho and both human FGFR1C and human β-klotho
UA109888C2 (uk) 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
EP2512503A4 (en) 2009-12-18 2013-08-21 Univ Indiana Res & Tech Corp COAGONISTS OF GLUCAGON / GLP-1 RECEPTOR
RU2012136450A (ru) 2010-01-27 2014-03-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Конъюгаты антагонист глюкагона - агонист gip и композиции для лечения метаболических расстройств и ожирения
EP2371857A1 (en) 2010-04-01 2011-10-05 CSL Behring GmbH Factor XII inhibitors for treating interstitial lung disease
WO2011130417A2 (en) 2010-04-15 2011-10-20 Amgen Inc. HUMAN FGF RECEPTOR AND β-KLOTHO BINDING PROTEINS
RU2012151296A (ru) 2010-04-30 2014-06-10 Санва Кагаку Кенкюсо Ко., Лтд Пептид для улучшения биостабильности биоактивного вещества и биоактивное вещество, имеющее повышенную биостабильность
JP6121323B2 (ja) 2010-05-13 2017-05-10 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ 核内ホルモン受容体の活性を示すグルカゴンスーパーファミリーのペプチド
WO2011143208A1 (en) 2010-05-13 2011-11-17 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhibiting g protein-coupled receptor activity
CN101891823B (zh) 2010-06-11 2012-10-03 北京东方百泰生物科技有限公司 一种Exendin-4及其类似物融合蛋白
WO2011163012A2 (en) 2010-06-24 2011-12-29 Indiana University Research And Technology Corporation Amide based glucagon superfamily peptide prodrugs
WO2012010553A1 (en) * 2010-07-20 2012-01-26 Novo Nordisk A/S N-terminal modified fgf21 compounds
BR112013015389A2 (pt) 2010-12-22 2016-11-22 Univ Indiana Res & Tech Corp análogo de glucagon exibindo atividade de receptor gip
WO2012097333A2 (en) 2011-01-14 2012-07-19 Redwood Bioscience, Inc. Aldehyde-tagged immunoglobulin polypeptides and method of use thereof
EP2497489A1 (en) 2011-03-09 2012-09-12 CSL Behring GmbH Factor XII inhibitors for the treatment of silent brain ischemia and ischemia of other organs
PL2683397T3 (pl) 2011-03-09 2018-01-31 Csl Behring Gmbh Inhibitory czynnika XII do podawania w zabiegach medycznych obejmujących kontakt z powierzchniami sztucznymi
US8969526B2 (en) 2011-03-29 2015-03-03 Roche Glycart Ag Antibody Fc variants
HUE035776T2 (en) 2011-06-22 2018-05-28 Univ Indiana Res & Tech Corp Glucagon / GLP-1 receptor coagulants
MX2013015168A (es) 2011-06-22 2014-03-31 Univ Indiana Res & Tech Corp Co-agonista del receptor de glucagon/glp-1.
IL230564B2 (en) 2011-07-22 2023-09-01 Csl Ltd Anticoagulant monoclonal antibodies anti–factor xii/fxiia, a method for their preparation, a pharmaceutical compound containing them and medical uses.
UY34317A (es) 2011-09-12 2013-02-28 Genzyme Corp Anticuerpo antireceptor de célula T (alfa)/ß
KR20130049671A (ko) 2011-11-04 2013-05-14 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
RU2014117678A (ru) 2011-11-17 2015-12-27 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Пептиды глюкагонового суперсемейства, обладающие глюкокортикоидной рецепторной активностью
EP2623110A1 (en) 2012-01-31 2013-08-07 CSL Behring GmbH Factor XII inhibitors for the treatment of neurological inflammatory disorders
DK2814502T3 (en) 2012-02-15 2017-12-18 Csl Behring Gmbh Von Willebrand Factor variants with improved Factor VIII binding affinity
US9340600B2 (en) 2012-06-21 2016-05-17 Indiana University Research And Technology Corporation Glucagon analogs exhibiting GIP receptor activity
WO2014009465A1 (en) 2012-07-13 2014-01-16 Roche Glycart Ag Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
US9790268B2 (en) 2012-09-12 2017-10-17 Genzyme Corporation Fc containing polypeptides with altered glycosylation and reduced effector function
JP6438397B2 (ja) * 2012-09-12 2018-12-12 ジェンザイム・コーポレーション 変更されたグリコシル化および低減されたエフェクター機能を有するＦｃ含有ポリペプチド
EP2926834A4 (en) 2012-11-27 2016-04-20 Alteogen Inc COMPOSITION FOR STABILIZING A FUSION PROTEIN IN WHICH A PROTEIN AND A DOMAIN FC ARE MERGED
ES2729997T3 (es) 2012-11-27 2019-11-07 Biomarin Pharm Inc Proteínas de fusión terapéuticas dirigidas de enzima lisosómica y usos de las mismas
KR102403299B1 (ko) 2013-03-08 2022-06-03 체에스엘 베링 게엠베하 원격 허혈-재관류 손상의 치료 및 예방
RU2711935C2 (ru) 2013-03-11 2020-01-23 Джензим Корпорейшн Сайт-специфическая конъюгация антитело-лекарственное средство посредством гликоинженерии
US9580486B2 (en) 2013-03-14 2017-02-28 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
WO2014158900A1 (en) 2013-03-14 2014-10-02 Indiana University Research And Technology Corporation Insulin-incretin conjugates
ES2657291T3 (es) 2013-04-22 2018-03-02 Csl Ltd. Un complejo covalente de factor de von Willebrand y factor VIII asociado por un puente disulfuro
CN105339010A (zh) 2013-06-28 2016-02-17 德国杰特贝林生物制品有限公司 使用因子xii抑制剂和c1-抑制剂的联合疗法
CN103408669B (zh) * 2013-08-01 2016-01-20 江苏泰康生物医药有限公司 Glp-1类似物融合蛋白，及其制备方法和用途
CN104592381A (zh) * 2013-10-31 2015-05-06 江苏万邦生化医药股份有限公司 一种利拉鲁肽中间体多肽的制备方法
US20170065678A1 (en) 2014-03-11 2017-03-09 Novartis Ag Methods of treating metabolic disorders associated with lipodystrophies and defects in insulin production or signaling
CA2942769A1 (en) 2014-03-19 2015-09-24 Genzyme Corporation Site-specific glycoengineering of targeting moieties
EA201691795A1 (ru) * 2014-03-31 2017-03-31 Ханми Фарм. Ко., Лтд. Способ улучшения растворимости белка и пептида за счет использования связывания с фрагментом fc иммуноглобулина
DK3157548T3 (da) 2014-06-18 2021-09-06 Csl Behring Gmbh Terapi anvendelse af en faktor xii-inhibitor i en neurotraumatisk sygdom
WO2016000039A1 (en) 2014-07-02 2016-01-07 Csl Limited Modified von willebrand factor
RS59789B1 (sr) 2014-07-21 2020-02-28 Delinia Inc Molekuli koji selektivno aktiviraju regulatorne t ćelije u tretmanima autoimunih bolesti
KR20170035910A (ko) 2014-08-11 2017-03-31 데리니아, 인크. 자가면역 질환의 치료를 위한 조절 t 세포를 선택적으로 활성화시키는 변형된 il-2 변이체
EP3206710B1 (en) 2014-09-24 2020-05-06 Indiana University Research & Technology Corporation Incretin-insulin conjugates
CN104293834B (zh) * 2014-10-11 2018-03-23 上海兴迪金生物技术有限公司 GLP‑1或其类似物与抗体Fc片段融合蛋白的制备方法
WO2016102562A1 (en) 2014-12-23 2016-06-30 Novo Nordisk A/S Fgf21 derivatives and uses thereof
KR101825048B1 (ko) * 2014-12-31 2018-02-05 주식회사 제넥신 GLP 및 면역글로불린 하이브리드 Fc 융합 폴리펩타이드 및 이의 용도
EA201792250A1 (ru) 2015-04-10 2018-05-31 Эмджен Инк. Мутеины интерлейкина-2 для роста регуляторных т-клеток
AR105616A1 (es) 2015-05-07 2017-10-25 Lilly Co Eli Proteínas de fusión
SG11201708755WA (en) 2015-05-22 2017-12-28 Csl Behring Recombinant Facility Ag Truncated von willebrand factor polypeptides for treating hemophilia
AU2016267539B2 (en) 2015-05-22 2019-12-05 CSL Behring Lengnau AG Methods for preparing modified von willebrand factor
TWI622596B (zh) 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
CN108350054B (zh) 2015-10-28 2022-09-02 株式会社柳韩洋行 双功能蛋白质和包含其的药物组合物
LT3368554T (lt) 2015-10-28 2020-09-25 Yuhan Corporation Ilgo veikimo fgf21 sulieti baltymai ir juos apimanti farmacinė kompozicija
EP3184149A1 (en) 2015-12-23 2017-06-28 Julius-Maximilians-Universität Würzburg Soluble glycoprotein v for treating thrombotic diseases
JP6948330B2 (ja) 2015-12-23 2021-10-13 アムジエン・インコーポレーテツド 胃抑制ペプチド受容体（ｇｉｐｒ）に対する結合タンパク質をｇｌｐ−１アゴニストと組み合わせて使用する、代謝障害の治療方法または寛解方法
KR20180094114A (ko) 2016-01-07 2018-08-22 체에스엘 베링 리컴비넌트 퍼실리티 아게 돌연변이된 절단된 폰 빌레브란트 인자
SG11201805494WA (en) 2016-01-07 2018-07-30 Csl Behring Recombinant Facility Ag Mutated von willebrand factor
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
JP7456723B2 (ja) 2016-04-06 2024-03-27 シーエスエル、リミテッド アテローム性動脈硬化症の治療方法
WO2017189432A1 (en) 2016-04-26 2017-11-02 R.P. Scherer Technologies, Llc Antibody conjugates and methods of making and using the same
US10336812B2 (en) 2016-05-10 2019-07-02 Janssen Biotech, Inc. GDF15 fusion proteins and uses thereof
WO2018032638A1 (zh) 2016-08-19 2018-02-22 安源医药科技（上海）有限公司 用于构建融合蛋白的连接肽
CN106279437B (zh) 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途
CN107759694B (zh) 2016-08-19 2023-01-13 安源医药科技（上海）有限公司 双特异性抗体及其制备方法与用途
WO2018089420A1 (en) 2016-11-08 2018-05-17 Delinia, Inc. Il-2 variants for the treatment of autoimmune diseases
WO2018088838A1 (en) 2016-11-10 2018-05-17 Yuhan Corporation Pharmaceutical composition for preventing or treating hepatitis, hepatic fibrosis, and hepatic cirrhosis comprising fusion proteins
ES2869339T3 (es) 2016-11-11 2021-10-25 CSL Behring Lengnau AG Polipéptidos del factor von Willebrand truncados para el tratamiento de la hemofilia
US11890327B2 (en) 2016-11-11 2024-02-06 CSL Behring Lengnau AG Truncated von Willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder
EP3351262A1 (en) 2016-12-30 2018-07-25 Istanbul Universitesi Rektorlugu Curaglutide for in treatment of prediabetes, diabetes, obesity and metabolic diseases associated thereto
JOP20190177A1 (ar) 2017-01-17 2019-07-16 Amgen Inc طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr)
KR102664780B1 (ko) 2017-04-21 2024-05-13 주식회사유한양행 이중 작용 단백질 및 그의 유도체의 제조방법
US20200171129A1 (en) 2017-06-01 2020-06-04 Eli Lilly And Company Therapeutic uses of dulaglutide
PL3641800T3 (pl) 2017-06-22 2024-03-18 CSL Behring Lengnau AG Modulacja immunogenności fviii przez skrócony vwf
WO2019060653A1 (en) 2017-09-22 2019-03-28 Regeneron Pharmaceuticals, Inc. GLP-1 RECEPTOR AGONISTS (GLUCAGON-LIKE PEPTIDE 1) AND USES THEREOF
KR102589234B1 (ko) 2017-11-21 2023-10-16 일라이 릴리 앤드 캄파니 둘라글루티드를 함유하는 조성물 및 사용 방법
CN111518770B (zh) 2017-12-19 2023-01-06 北京吉源生物科技有限公司 一种表达glp1和fgf21的干细胞及其用途
US11491235B2 (en) 2017-12-22 2022-11-08 Kb Biomed Inc. Oral gene carrier and use thereof
WO2019140021A1 (en) 2018-01-12 2019-07-18 Eli Lilly And Company Combination therapy
JP7475276B2 (ja) 2018-02-08 2024-04-26 サンシャイン・レイク・ファーマ・カンパニー・リミテッド Ｆｇｆ２１バリアント、融合タンパク質及びそれらの適用
KR20200135618A (ko) 2019-05-23 2020-12-03 ㈜ 디앤디파마텍 폴리펩티드를 포함하는 비알코올성 지방간 질환의 예방 또는 치료용 약학 조성물
EP3823659A4 (en) 2018-07-19 2022-06-22 D&D Pharmatech Inc. PHARMACEUTICAL COMPOSITION WITH A POLYPEPTIDE
CN110878127B (zh) 2018-09-06 2022-06-28 浙江柏拉阿图医药科技有限公司 长效重组GLP1-Fc-CD47蛋白及其制备和用途
CN111234000B (zh) * 2018-11-28 2023-05-26 鲁南制药集团股份有限公司 艾塞纳肽类似物
CN111269312B (zh) * 2018-12-04 2023-05-09 鲁南制药集团股份有限公司 一种异源融合蛋白质
CN109836486B (zh) * 2019-01-30 2020-09-08 北京双因生物科技有限公司 成纤维生长因子21变体、其融合蛋白及其用途
CN111662373B (zh) * 2019-03-05 2024-05-14 广东东阳光药业股份有限公司 一种多肽分子及其应用
MX2021010737A (es) 2019-03-08 2021-09-28 Amgen Inc Terapia de combinacion por factor de diferenciacion del crecimiento 15.
WO2020190591A1 (en) 2019-03-15 2020-09-24 Eli Lilly And Company Preserved formulations
CA3177693A1 (en) 2019-04-05 2020-10-05 Eli Lilly And Company Therapeutic uses of dulaglutide
JP2022533365A (ja) 2019-05-17 2022-07-22 ウニベルシテート チューリッヒ 出血性脳卒中後の有害な二次神経学的転帰を処置する際に使用するためのハプトグロビン
EP3994162A1 (en) 2019-07-04 2022-05-11 CSL Behring Lengnau AG A truncated von willebrand factor (vwf) for increasing the in vitro stability of coagulation factor viii
JP2022552323A (ja) 2019-10-15 2022-12-15 イーライ リリー アンド カンパニー 組換え操作された、リパーゼ／エステラーゼ欠損哺乳動物細胞株
EP4058049A1 (en) 2019-11-11 2022-09-21 CSL Behring Lengnau AG Polypeptides for inducing tolerance to factor viii
CN113728013B (zh) 2020-01-11 2022-06-14 北京质肽生物医药科技有限公司 Glp-1和fgf21的融合蛋白的缀合物
US11981718B2 (en) 2020-05-27 2024-05-14 Ampsource Biopharma Shanghai Inc. Dual-function protein for lipid and blood glucose regulation
EP4200429A1 (en) 2020-08-24 2023-06-28 The Trustees of The University of Pennsylvania Viral vectors encoding glp-1 receptor agonist fusions and uses thereof in treating metabolic diseases
CN114106194B (zh) * 2020-08-31 2024-01-16 中国科学院天津工业生物技术研究所 一种用于治疗糖尿病和/或肥胖症的融合蛋白
US20240000908A1 (en) 2020-11-20 2024-01-04 Csl Behring Gmbh Method for Treating Antibody-Mediated Rejection
CN114685644A (zh) 2020-12-29 2022-07-01 苏州康宁杰瑞生物科技有限公司 一种人glp-1多肽变体及其应用
JP2024504822A (ja) 2021-02-01 2024-02-01 ツェー・エス・エル・ベーリング・アクチエンゲゼルシャフト 出血性脳卒中後の有害な二次神経学的転帰を処置または予防する方法
JP2024517857A (ja) 2021-05-07 2024-04-23 ツェー・エス・エル・ベーリング・アクチエンゲゼルシャフト 組換えハプトグロビン（Ｈｐ）ベータ鎖を作製するための発現系
CN117616037A (zh) 2021-07-06 2024-02-27 苏州康宁杰瑞生物科技有限公司 融合蛋白及其应用
WO2023225534A1 (en) 2022-05-18 2023-11-23 Protomer Technologies Inc. Aromatic boron-containing compounds and related insulin analogs
CN114774496B (zh) * 2022-06-21 2022-10-04 北京惠之衡生物科技有限公司 一种高密度发酵制备glp-1类似物的方法
WO2024047219A1 (en) 2022-09-02 2024-03-07 Csl Behring Ag Haptoglobin for use in treating or preventing exaggerated erectile response or erectile dysfunction
WO2024064842A1 (en) 2022-09-21 2024-03-28 Regeneron Pharmaceuticals, Inc. Methods of treating obesity, diabetes, and liver dysfunction
WO2024068848A1 (en) 2022-09-28 2024-04-04 Zealand Pharma A/S Methods for treating obesity

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4943529A (en) 1982-05-19 1990-07-24 Gist-Brocades Nv Kluyveromyces as a host strain
AU3145184A (en) 1983-08-16 1985-02-21 Zymogenetics Inc. High expression of foreign genes in schizosaccharomyces pombe
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
JP3101690B2 (ja) * 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5010182A (en) 1987-07-28 1991-04-23 Chiron Corporation DNA constructs containing a Kluyveromyces alpha factor leader sequence for directing secretion of heterologous polypeptides
AU4005289A (en) 1988-08-25 1990-03-01 Smithkline Beecham Corporation Recombinant saccharomyces
DE68927344T2 (de) 1989-04-28 1997-02-20 Rhein Biotech Proz & Prod Gmbh Hefezellen der Gattung-Schwanniomyces
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
FR2649120B1 (fr) 1989-06-30 1994-01-28 Cayla Nouvelle souche et ses mutants de champignons filamenteux, procede de production de proteines recombinantes a l'aide de ladite souche et souches et proteines obtenues selon ce procede
PT669929E (pt) * 1992-11-13 2007-04-30 Immunex Corp Ligando de elk, uma citoquina
AU3382595A (en) * 1994-07-29 1996-03-04 Smithkline Beecham Corporation Novel compounds
GB9511935D0 (en) 1995-06-13 1995-08-09 Smithkline Beecham Plc Novel compound
US5723125A (en) * 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
US6750334B1 (en) 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
US6006753A (en) 1996-08-30 1999-12-28 Eli Lilly And Company Use of GLP-1 or analogs to abolish catabolic changes after surgery
US6277819B1 (en) 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
UA65549C2 (uk) * 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
US6190909B1 (en) * 1997-04-17 2001-02-20 Millennium Pharmaceuticals, Inc. TH2-specific gene
SE9802080D0 (sv) 1998-06-11 1998-06-11 Hellstroem Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein
EP1100530B1 (en) 1998-07-31 2003-10-08 Novo Nordisk A/S In-vitro stimulation of beta cell proliferation
MY155270A (en) 1998-09-24 2015-09-30 Lilly Co Eli Use of glp-1 or analogs in treatment of stroke
US6376653B1 (en) * 1998-09-28 2002-04-23 Smithkline Beecham Plc Tie2 antagonist antibodies
EA003922B1 (ru) 1999-05-17 2003-10-30 Конджачем, Инк. Продолжительно действующие инсулинотропные пептиды
DK1294757T3 (da) 2000-06-16 2007-03-19 Lilly Co Eli Glucagonlignende peptid 1-analoger
DK1724284T3 (da) * 2000-12-07 2009-11-02 Lilly Co Eli GLP-1 fusionsproteiner
US6992174B2 (en) * 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
US6900292B2 (en) * 2001-08-17 2005-05-31 Lee-Hwei K. Sun Fc fusion proteins of human erythropoietin with increased biological activities
EP1463751B1 (en) * 2001-12-21 2013-05-22 Human Genome Sciences, Inc. Albumin fusion proteins
WO2005000892A2 (en) * 2003-06-12 2005-01-06 Eli Lilly And Company Glp-1 analog fusion plroteins

Also Published As

Publication number Publication date
EA008831B1 (ru) 2007-08-31
BRPI0411132A (pt) 2006-07-18
CN101974090A (zh) 2011-02-16
CY2015002I1 (el) 2015-11-04
CN1802386A (zh) 2006-07-12
US8273854B2 (en) 2012-09-25
IL171926A (en) 2010-12-30
PT1641823E (pt) 2011-11-08
BRPI0411132B1 (pt) 2016-12-13
CN1802386B (zh) 2010-12-15
EP2368909A1 (en) 2011-09-28
MXPA05013565A (es) 2006-03-09
FR15C0010I2 (fr) 2015-07-24
UA87458C2 (ru) 2009-07-27
PL1641823T3 (pl) 2012-02-29
EP1641823A2 (en) 2006-04-05
DK1641823T3 (da) 2011-12-12
SI1641823T1 (sl) 2011-12-30
US7452966B2 (en) 2008-11-18
HUS1500024I1 (hu) 2017-04-28
CA2528591A1 (en) 2005-01-06
CY2015002I2 (el) 2017-04-05
CN101974090B (zh) 2015-06-17
WO2005000892A2 (en) 2005-01-06
CY1111991T1 (el) 2015-11-04
WO2005000892A3 (en) 2005-03-03
JP4629047B2 (ja) 2011-02-09
ES2371072T3 (es) 2011-12-27
HRP20110714T1 (hr) 2011-11-30
KR100758755B1 (ko) 2007-09-14
LTC1641823I2 (lt) 2016-12-12
EP1641823B1 (en) 2011-09-21
IL171926A0 (en) 2006-04-10
AU2004251145B2 (en) 2010-09-09
CA2528591C (en) 2013-01-08
US20070036806A1 (en) 2007-02-15
HK1149566A1 (en) 2011-10-07
NZ543292A (en) 2008-04-30
TW200507870A (en) 2005-03-01
JP2007536902A (ja) 2007-12-20
AU2004251145A1 (en) 2005-01-06
US20090074769A1 (en) 2009-03-19
EA200600015A1 (ru) 2006-06-30
ATE525395T1 (de) 2011-10-15
KR20060022262A (ko) 2006-03-09
AR044776A1 (es) 2005-10-05
BRPI0411132B8 (pt) 2021-05-25
FR15C0010I1 (US07576130-20090818-C00078.png) 2015-03-13
AU2004251145C1 (en) 2011-04-14

Similar Documents

Publication Publication Date Title
BE2015C007I2 (US07576130-20090818-C00078.png)
BE2014C055I2 (US07576130-20090818-C00078.png)
BE2014C027I2 (US07576130-20090818-C00078.png)
BE2014C003I2 (US07576130-20090818-C00078.png)
BE2013C075I2 (US07576130-20090818-C00078.png)
BE2013C069I2 (US07576130-20090818-C00078.png)
BE2013C067I2 (US07576130-20090818-C00078.png)
BE2013C038I2 (US07576130-20090818-C00078.png)
BE2013C036I2 (US07576130-20090818-C00078.png)
BE2011C030I2 (US07576130-20090818-C00078.png)
JP2003314704A5 (US07576130-20090818-C00078.png)
JP2003240894A5 (US07576130-20090818-C00078.png)
BE2015C005I2 (US07576130-20090818-C00078.png)
JP2003319467A5 (US07576130-20090818-C00078.png)
BE2012C053I2 (US07576130-20090818-C00078.png)
JP2003248810A5 (US07576130-20090818-C00078.png)
JP2004047465A5 (US07576130-20090818-C00078.png)
JP2004096719A5 (US07576130-20090818-C00078.png)
JP2004142459A5 (US07576130-20090818-C00078.png)
DE502004007013D1 (US07576130-20090818-C00078.png)
JP2004066812A5 (US07576130-20090818-C00078.png)
JP2004208683A5 (US07576130-20090818-C00078.png)
JP2004067074A5 (US07576130-20090818-C00078.png)
JP2003341249A5 (US07576130-20090818-C00078.png)
JP2004053012A5 (US07576130-20090818-C00078.png)